Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Lung T3 Treatment for COVID-19 ARDS
NCT04725110Phase 2Withdrawn
- Sponsor
- University of Minnesota
- Start
- Jan 2026
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liothyronine in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by University of Minnesota. Planned start Jan 2026; status: withdrawn.
02
Drugs
liothyronine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04725110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725110.